# Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR

Study · id `cardio:ct-nct07129421` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07129421](<https://clinicaltrials.gov/study/NCT07129421>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07129421

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 560 participants.

## Technical summary

Registry record NCT07129421. Randomized; single masking; primary purpose prevention. Start 2025-10-21 (anticipated); primary completion 2027-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 560 participants (planned count; ClinicalTrials.gov record NCT07129421, source copy `cardio:ctgov-nct07129421-2025-08-19`, retrieved 2026-10-26)
- Planned start: 2025-10-21 (anticipated) (ClinicalTrials.gov record NCT07129421, source copy `cardio:ctgov-nct07129421-2025-08-19`, retrieved 2026-10-26)
- Primary completion: 2027-01-31 (anticipated) (ClinicalTrials.gov record NCT07129421, source copy `cardio:ctgov-nct07129421-2025-08-19`, retrieved 2026-10-26)
- Completion: 2027-03-15 (anticipated) (ClinicalTrials.gov record NCT07129421, source copy `cardio:ctgov-nct07129421-2025-08-19`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07129421-2025-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR
- Acronym: EMBLOK II
- Condition: AORTIC VALVE DISEASES
- Condition: Aortic Valve Stenosis and/or Insufficiency
- Condition: Aortic Valve Regurgitation
- Condition: Aortic Valve Replacement
- Intervention (Device): EMBLOK™ Embolic Protection System ("EMBLOK EPS")
- Lead sponsor: Emblok, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Yale Cardiovascular Research Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as a collaborator: Yale Cardiovascular Research Group (`cardio:org-yale-cardiovascular-research-group`)

## Provenance

Content hash: b4f9a2cd202665bf9cf231eb4c481fe7d5c419a307d902d3e3b6b8518e24b93d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
